Atorvastatin and Conditioned Media from Atorvastatin-Treated Human Hematopoietic Stem/Progenitor-Derived Cells Show Proangiogenic Activity In Vitro but Not In Vivo

Figure 1

Gating for sorting of CD34⁺7AAD^- cells. CD34⁺7AAD^- cells constituted 1.6-2% of cryostored PBMCs (a); CD34⁺ cells constituted 1.53% of fresh isolated PBMCs. In majority, they were positive for CD133 (68.8%) and negative for most of tested markers: CD11b, CD14, CD16, CXCR4, and CD105, and 21.9% of them were positive for CD90. Phenotyping of obtained PBMCs was assessed with flow cytometry. Cells (b), Hoechst⁺ nucleated cells (c), singlets (d), Lin^- cells (e), CD34⁺ or CD34⁺CD133⁺ cells within Lin^-Hoe⁺ cells (f), CD34⁺ cells within nucleated cells (g), CXCR4 vs. CD133 within CD34⁺ cells (h), CD11b vs. CD133 within CD34⁺ cells (i), CD181 vs. CD133 within CD34⁺ cells (j), CD16 vs. CD14 within CD34⁺ cells (k), and CD90 vs. CD105 within CD34⁺ cells (l).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)